Pd-Rx Pharmaceutical Valuation
| PDRX Stock | USD 2.90 0.00 0.00% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. Pd Rx Pharmaceutical owns a latest Real Value of $2.63 per share. The recent price of the company is $2.9. Our model determines the value of Pd Rx Pharmaceutical from evaluating the company fundamentals such as revenue of 21.6 M, and Return On Asset of 0.0556 as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Pd-Rx Pharmaceutical's price fluctuation is somewhat reliable at this time. Calculation of the real value of Pd Rx Pharmaceutical is based on 3 months time horizon. Increasing Pd-Rx Pharmaceutical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Pd-Rx Pharmaceutical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Pd-Rx Pink Sheet. However, Pd-Rx Pharmaceutical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.9 | Real 2.63 | Hype 2.9 | Naive 2.93 |
The intrinsic value of Pd-Rx Pharmaceutical's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Pd-Rx Pharmaceutical's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Pd Rx Pharmaceutical helps investors to forecast how Pd-Rx pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Pd-Rx Pharmaceutical more accurately as focusing exclusively on Pd-Rx Pharmaceutical's fundamentals will not take into account other important factors: Pd-Rx Pharmaceutical Total Value Analysis
Pd Rx Pharmaceutical is at this time projected to have valuation of 4.45 M with market capitalization of 10.29 M, debt of 466.84 K, and cash on hands of 104.55 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Pd-Rx Pharmaceutical fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
4.45 M | 10.29 M | 466.84 K | 104.55 K |
Pd-Rx Pharmaceutical Investor Information
The company last dividend was issued on the 13th of December 2018. Pd Rx Pharmaceutical is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Pd-Rx Pharmaceutical Asset Utilization
One of the ways to look at asset utilization of Pd-Rx is to check how much profit was generated for every dollar of assets it reports. Pd-Rx Pharmaceutical operates its current and long term assets around 0.0556 %, generating 0.0556 cents for each dollar of current and long term assets held by the company. An accumulating asset utilization implies the company is being more productive with each dollar of current and long term assets it owns. Strictly speaking, asset utilization of Pd-Rx Pharmaceutical shows how productive it operates for each dollar spent on its current and long term assets.Pd-Rx Pharmaceutical Profitability Analysis
The company reported the previous year's revenue of 21.6 M. Net Income was 1.86 M with profit before overhead, payroll, taxes, and interest of 6.96 M.About Pd-Rx Pharmaceutical Valuation
Our relative valuation model uses a comparative analysis of Pd-Rx Pharmaceutical. We calculate exposure to Pd-Rx Pharmaceutical's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Pd-Rx Pharmaceutical's related companies.PD-Rx Pharmaceuticals, Inc. engages in the repackaging and distribution of prepackaged pharmaceutical products for the healthcare industry in the United States. PD-Rx Pharmaceuticals, Inc. was incorporated in 1986 and is headquartered in Oklahoma City, Oklahoma. Pd-Rx Pharmaceutical operates under Medical Distribution classification in the United States and is traded on OTC Exchange.
8 Steps to conduct Pd-Rx Pharmaceutical's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Pd-Rx Pharmaceutical's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Pd-Rx Pharmaceutical's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Pd-Rx Pharmaceutical's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Pd-Rx Pharmaceutical's revenue streams: Identify Pd-Rx Pharmaceutical's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Pd-Rx Pharmaceutical's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Pd-Rx Pharmaceutical's growth potential: Evaluate Pd-Rx Pharmaceutical's management, business model, and growth potential.
- Determine Pd-Rx Pharmaceutical's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Pd-Rx Pharmaceutical's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Pd-Rx Pharmaceutical Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Quarterly Earnings Growth Y O Y | 0.604 | |
| Retained Earnings | 7.4 M |
Additional Tools for Pd-Rx Pink Sheet Analysis
When running Pd-Rx Pharmaceutical's price analysis, check to measure Pd-Rx Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pd-Rx Pharmaceutical is operating at the current time. Most of Pd-Rx Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Pd-Rx Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pd-Rx Pharmaceutical's price. Additionally, you may evaluate how the addition of Pd-Rx Pharmaceutical to your portfolios can decrease your overall portfolio volatility.